Associations - EGFR expression

BIOMARKER:

EGFR expression

Entrez ID:

1956

Related biomarkers:

‹

›

EGFR expression EGFR expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	necitumumab Sensitive: A1 - Approval necitumumab Sensitive : A1
EGFR expression EGFR expression	Colorectal Cancer CRC	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
EGFR expression EGFR expression	Chordoma Chordoma	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B
EGFR expression EGFR expression	Colorectal Cancer CRC	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B
EGFR expression EGFR expression	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR expression EGFR expression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: C1 - Off-label cetuximab Sensitive : C1
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
EGFR expression EGFR expression	Ovarian Cancer Ovarian Cancer	gefitinib Resistant: C2 – Inclusion Criteria gefitinib Resistant : C2
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
EGFR expression EGFR expression	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	trastuzumab + erlotinib Sensitive: C3 – Early Trials trastuzumab + erlotinib Sensitive : C3
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3
EGFR expression EGFR expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	gefitinib + fulvestrant Sensitive: C3 – Early Trials gefitinib + fulvestrant Sensitive : C3
EGFR expression EGFR expression	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3
EGFR expression EGFR expression	Lung Adenocarcinoma LUAD	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4
EGFR expression EGFR expression	Glioblastoma GBM	paclitaxel Sensitive: D – Preclinical paclitaxel Sensitive : D
EGFR expression EGFR expression	Glioblastoma GBM	selumetinib Sensitive: D – Preclinical selumetinib Sensitive : D
EGFR expression EGFR expression	Glioma Glioma	gefitinib Sensitive: D – Preclinical gefitinib Sensitive : D
EGFR expression EGFR expression	Squamous Cell Carcinoma of Head and Neck SCCHN	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D
EGFR expression EGFR expression	Pancreatic Cancer Pancreatic Cancer	afatinib Sensitive: D – Preclinical afatinib Sensitive : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES